2019 Event Guide

brochure cover

2019 Highlights Included:

The Discovery & Characterisation of a Novel Chemotype for Enhanced NLRP3 Inflammasome Inhibition & Tissue Penetration | Chris Gabel Vice President, Biology Nodthera
Pharmacology Inhibition of the NLRP3 Inflammasome | Matt Cooper Chief Executive Officer & Co-Founder Inflazome
Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory
Diseases | Rebecca Coll Principle Investigator Queen’s University Belfast